Compare Repligen Corporation Common Stock (RGEN) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Raytheon Technologies Corp — how do they compare? Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B), while Raytheon Technologies Corp trades at $189.44 (market cap $251.32B). The key difference: Raytheon Technologies Corp is far larger — about 22.2× Repligen Corporation Common Stock's market cap, and Raytheon Technologies Corp pays a 1.57% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Raytheon Technologies Corp for 78 Days on average.
| RGEN | RTX | |
|---|---|---|
Market Cap | $11.31B | $251.32B |
Volume | 1,216,919 | 4,046,219 |
Sector | Health | Industrials |
52-Week High | $194.57 | $225.49 |
52-Week Low | $102.87 | $157.00 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $11.20B | $281.87B |
Dividend Yield | — | 1.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
RTX trades at $183.02, down 1.95% today, amid a bearish technical signal. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.89 exceeding the $1.66 estimate. Revenue grew to $88.60 billion in 2025, and the net income margin improved to 7.59%. A robust $289 billion backlog and positive defense budget trends underpin growth prospects, though elevated debt levels and a high P/E ratio of 32.22 present valuation concerns.
The outlook remains positive given analyst consensus, with a $233.55 price target implying significant upside. Key opportunities include sustained defense demand and commercial aerospace recovery. Risks involve execution on the large backlog, interest expense from debt, and geopolitical uncertainties affecting defense spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
